ID   K562-ARA-C
AC   CVCL_Z732
SY   K/araC
DR   Wikidata; Q54899377
RX   PubMed=10500836;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 29-06-23; Version: 16
//
RX   PubMed=10500836; DOI=10.1007/978-1-4615-4811-9_63;
RA   Dumontet C., Callet-Bauchu E., Fabianowska K., Lepoivre M.,
RA   Wyczechowska D., Bodin F., Rolland M.-O.;
RT   "Common resistance mechanisms to nucleoside analogues in variants of
RT   the human erythroleukemic line K562.";
RL   Adv. Exp. Med. Biol. 457:571-577(1999).
//